Omentin-1 levels in patients with premature coronary artery disease, metabolic syndrome and healthy controls. Short communication.
OBJECTIVE
Omentin-1 is an adipokine which could have a protective role against the manifestation of atherosclerosis. Only limited data are available on omentin-1 serum values in patients with premature clinical manifestations of atherosclerosis.


METHODS
We tested omentin-1 in human serum by ELISA method in 61 individuals with a premature manifestation of coronary artery disease (CAD), 40 patients with metabolic syndrome and 40 healthy control subjects.


RESULTS
Omentin-1 serum levels were significantly lower in patients with CAD (103.1±62.7 mg/L) compared to metabolic syndrome (668.2±339.6 mg/L) and healthy subjects (623.0±373.5 mg/L) (P < 0.01). In CAD patients, omentin-1 serum levels did not differ between patients sampled in the acute phase of myocardial infarction (n = 28; 110.3±82.4 mg/L) and in the chronic phase several months or years after myocardial infarction (n = 33; 97.0±39.3 mg/L) (P = 0.41). We found a weak positive correlation between omentin-1 and body mass index (r = 0.21, P = 0.014). No significant correlation was found between peak cardiac troponin T and omentin-1 (correlation coefficient r = 0.118, P = 0.406).


CONCLUSIONS
Serum omentin-1 seems to be a useful biomarker of coronary artery disease across the whole age spectrum.
AGEL Research and Training Institute, Prostejov, Czech Republic.|Institute of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.|Department of Biomedical Sciences, Faculty of Medicine, Ostrava University, Czech Republic.
David
D
Stejskal
Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Jan
J
Vaclavik
Department of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Ales
A
Smekal
AGEL Research and Training Institute, Prostejov, Czech Republic.|Institute of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Gabriela
G
Svobodova
Agel Laboratories, Novy Jicin, Czech Republic.
Radmila
R
Richterova
AGEL Research and Training Institute, Prostejov, Czech Republic.|Institute of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Marek
M
Svestak
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood / Q000175:diagnosis*; D016207:Cytokines / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D058851:GPI-Linked Proteins / Q000378:metabolism; D006801:Humans; D037102:Lectins / Q000378:metabolism*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000175:diagnosis*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis; D012372:ROC Curve; D015203:Reproducibility of Results; D055815:Young Adult
D015415:Biomarkers; D016207:Cytokines; D058851:GPI-Linked Proteins; C432397:ITLN1 protein, human; D037102:Lectins
ELISA; acute myocardial infarction; adipokines; coronary artery disease; omentin-1; premature manifestation